Mesa Labs announces new segment reporting structure effective Q3 FY2022

MESA LABORATORIES INC /CO/

Four new segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions.
Clinical Genomics segment consists of recently acquired Agena Bioscience business.
Calibration Solutions combines former Instruments and Continuous Monitoring segments.
Over 90% of future revenues expected from pharma, medical device, and healthcare verticals.
Change reflects management's focus on higher-growth Life Sciences Tools applications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.